Aclaris Therapeutics Inc (ACRS) Stock: Analyzing Its Quiet Power

H.C. Wainwright has recently raised Aclaris Therapeutics Inc (ACRS) stock to Buy rating, as announced on December 23, 2024, according to Finviz. Earlier, on November 20, 2024, Cantor Fitzgerald had raised the stock from a Neutral to Overweight. Leerink Partners also raised Outperform rating with a price target of $7. Additionally, Jefferies raised Buy rating on November 19, 2024, with a target price of $7. BTIG Research analysts, in their report published on November 19, 2024, also raised Buy rating for Aclaris Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.

Aclaris Therapeutics Inc (ACRS) Stock Trading Recap

On Tuesday, Aclaris Therapeutics Inc (ACRS) stock saw a modest uptick, ending the day at $2.5 which represents a slight increase of $0.02 or 0.81% from the prior close of $2.48. The stock opened at $2.5 and touched a low of $2.31 during the day, reaching a high of $2.5. The volume of shares traded was 2.69 million exceeding the average volume of 2.55 million.


Sponsored

ACRS Stock Performance and Moving Averages

In recent trading, Aclaris Therapeutics Inc (ACRS) stock price has shown some volatility, fluctuating -1.19% over the last five trades and -29.38% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 85.19%, and it has gained 111.86% in the previous three months. Currently, ACRS is trading at -8.23%, -17.20%, and 50.15% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.

As of the latest trading close, ACRS, a Healthcare sector stock, is trading -51.64% below its 52-week high but remains 162.74% above its 52-week low. The Average True Range (ATR) (14 days) of 0.25 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.

Aclaris Therapeutics Inc’s Profitability and Valuation Ratios

Aclaris Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of -208.45% and a profit margin of -136.65%, with a gross margin of 85.19%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.

In terms of valuation, Aclaris Therapeutics Inc’s market capitalization stands at $267.55 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 9.88, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 1.37, comparing the market value to the company’s book value.

Understanding Insider Trading

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.38% of Aclaris Therapeutics Inc (ACRS)’s shares, while financial institutions hold 50.49%.

Related Posts

Unlock Your Investment Potential: Get Your 100% Free eBook

Best Space Stocks To Buy

A detailed analysis of Three Best Space Stocks to Buy, each selected based on Innovations, Growth Metrics & Achievements

No thanks

Best Space Stocks to Buy!

Unlock Your Investment Potential: Get Your 100% Free eBook

A Detail Analysis of Three Best Space Stocks to Buy, Eash Selected Based on Innovations, Growth Metrics & Achievements